The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

In a crucial step towards understanding the mechanisms involved in cardiovascular disease and certain cancers, a Canadian led research team has succeeded in a world first: they've found the molecular ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients ...

ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A once-daily oral PCSK9 inhibitor reduced LDL in ...

Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will ...

PHILADELPHIA, PA—A novel, long-acting PCSK9 inhibitor that is injected just once every 3 months can reduce LDL-cholesterol levels by more than 50% compared with placebo in patients already taking ...

Chronic kidney disease is a growing problem globally. A new study from Aarhus University shows that a protein known for treating heart diseases also affects a mechanism in the kidney that reabsorbs ...

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616 ...